Jacqueline Capeau

Paris, 75012, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 124 publications

Corrigendum to 'Pink adipose tissue: A paradigm of adipose tissue plasticity' [Ann. Endocrinol. 85 (2004) 248-51].

Corrigendum to 'Pink adipose tissue: A paradigm of adipose tissue plasticity' [Ann. Endocrinol. 85 (2004) 248-51].

Journal: Annales d'endocrinologie
Published: June 30, 2026

Predictors of Cerebral Small-Vessel Disease in Middle-Aged, Virologically Controlled People Living With HIV.

Predictors of Cerebral Small-Vessel Disease in Middle-Aged, Virologically Controlled People Living With HIV.

Journal: Open forum infectious diseases
Published: March 11, 2026

Severe hyperglycemia after initiation of long-acting cabotegravir in two antiretroviral treatment-controlled people with HIV.

Severe hyperglycemia after initiation of long-acting cabotegravir in two antiretroviral treatment-controlled people with HIV.

Journal: Diabetes & metabolism
Published: February 23, 2026

Different Trends of Immune Activation Markers When Switching to Either Oral or Injectable Dual Antiretroviral Therapy Based on Integrase Inhibitors in People Living with HIV.

Different Trends of Immune Activation Markers When Switching to Either Oral or Injectable Dual Antiretroviral Therapy Based on Integrase Inhibitors in People Living with HIV.

Journal: Pathogens (Basel, Switzerland)
Published: February 09, 2026

Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial.

Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial.

Journal: BMJ open
Published: February 05, 2026

Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial.

Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial.

Journal: The lancet. HIV
Published: November 13, 2025

Myosteatosis in HIV: the adipose tissue connection.

Myosteatosis in HIV: the adipose tissue connection.

Journal: AIDS (London, England)
Published: June 11, 2025

The Effects of High-Dose Probiotic Supplementation on Immune Activation and Neurocognitive Disorders in People Living with HIV Undergoing Successful Antiretroviral Treatment: The Procog Study.

The Effects of High-Dose Probiotic Supplementation on Immune Activation and Neurocognitive Disorders in People Living with HIV Undergoing Successful Antiretroviral Treatment: The Procog Study.

Journal: Pathogens (Basel, Switzerland)
Published: April 29, 2025

C-C chemokine ligand 5 from women subcutaneous adipose tissue has a central role in vascular aging.

C-C chemokine ligand 5 from women subcutaneous adipose tissue has a central role in vascular aging.

Journal: Cardiovascular diabetology
Published: March 18, 2025

Cost-effectiveness of a 4 days-a-week triple therapy in persons with HIV: an ancillary study of the QUATUOR trial.

Cost-effectiveness of a 4 days-a-week triple therapy in persons with HIV: an ancillary study of the QUATUOR trial.

Journal: AIDS (London, England)
Published: December 17, 2024

Pink adipose tissue: A paradigm of adipose tissue plasticity.

Pink adipose tissue: A paradigm of adipose tissue plasticity.

Journal: Annales d'endocrinologie
Published: June 13, 2024

HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals.

HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals.

Journal: Annales d'endocrinologie
Published: June 13, 2024
Showing 1-12 of 124

Last Updated: 09/26/2026